A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Summary

This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.

Timeline

Start

2014-03-14

Primary completion

2016-03-24

Completion

2020-03-12

Drugs

Indications